TNFRSF17 and Miyoshi myopathy: In addition, Harpoon Therapeutics is currently investigating a novel trispecific TCE (HPN217) targeting T cells, MM, and albumin using anti-CD3, anti-BCMA, and anti-albumin, respectively.